Browsing Tag
NASDAQ: EPIX
1 post
ESSA Pharma shareholders approve XenoTherapeutics acquisition as investors weigh biotech liquidation value
ESSA securityholders back XenoTherapeutics acquisition with 99% approval—learn how this deal reshapes biotech exit models and investor sentiment.